1. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1342,
2002,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
2. |
Ethical issues in paediatric cancer trials |
|
Inpharma Weekly,
Volume &NA;,
Issue 1342,
2002,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
3. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1342,
2002,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
4. |
Antipsychotics clearly beneficial in bipolar disorder |
|
Inpharma Weekly,
Volume &NA;,
Issue 1342,
2002,
Page 5-6
Kimberley Salmon,
Preview
|
|
摘要:
Bipolar disorder is a psychiatric condition that is both serious and costly. Indeed, bipolar disorder accounts for approximately $US7.6 million annually in direct healthcare costs in the US. Atypical antipsychotic drugs are increasingly being used to treat this disorder, instead of older, less costly conventional antipsychotics. Despite the higher acquisition costs associated with atypical antipsychotics, evidence suggests that their use may in fact lower overall healthcare costs, due to their favourable safety and efficacy profiles, compared with conventional antipsychotics. At the 7th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research [Arlington, Virginia, US; May 2002], three studies addressed the use of atypical antipsychotics in bipolar disorder, and the resulting impact on healthcare costs, resource use and hospitalisation.
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
5. |
Ramipril'highly cost-effective'in Sweden |
|
Inpharma Weekly,
Volume &NA;,
Issue 1342,
2002,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
6. |
Aspirin more cost effective than clopidogrel in the US |
|
Inpharma Weekly,
Volume &NA;,
Issue 1342,
2002,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
7. |
Amantadine'value for money'for influenza in the UK |
|
Inpharma Weekly,
Volume &NA;,
Issue 1342,
2002,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
8. |
Daptomycin - a new option for resistant Gram-positive infections |
|
Inpharma Weekly,
Volume &NA;,
Issue 1342,
2002,
Page 9-11
Pamela Hunter,
Preview
|
|
摘要:
Daptomycin ['Cidecin'] has demonstrated promising activity according to results from clinical studies presented at the 12th European Congress of Clinical Microbiology and Infectious Diseases [ECCMID; Milan, Italy; April 2002] and the Annual Meeting of the Surgical Infection Society (SIS) [Madrid, Spain; May 2002]. Treatment with daptomycin was shown to increase the survival rate in a phase II study of emergency use in febrile neutropenic patients with vancomycin-resistantEnterococcus faecium(VREF) infections. The prognosis for patients with febrile neutropenia is very poor and there is usually a high mortality rate, but 5 of the 10 daptomycin recipients survived in this study. In a second study, daptomycin was as effective as ciprofloxacin for treating complicated urinary tract infections (UTIs) caused by Gram-positive bacteria. Further analysis of data from two phase III studies in complicated skin and soft tissue infections (studies 9801 and 9901) produced results consistent with previously published data demonstrating efficacy and a trend towards a reduced duration of IV therapy with daptomycin; the new data showed that fever was more rapidly resolved in patients treated with daptomycin than in those receiving comparator antibacterials.
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
9. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1342,
2002,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
10. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1342,
2002,
Page 12-12
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|